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Aims. Nuclear translocation of β-catenin is common in many cancers including esophageal squamous cell carcinoma (ESCC). As
a mediator of Wnt signaling pathway, nuclear β-catenin can activate many growth-related genes including CCN1, which in turn
can induce β-catenin translocation. CCN1, a matricellular protein, signals through various integrin receptors in a cell-dependent
manner to regulate cell adhesion, proliferation, and survival. Its elevation has been reported in ESCC as well as other esophageal
abnormalities such as Barrett’s esophagus. The aim of this study is to examine the relationship between CCN1 and β-catenin in
ESCC. Methods and Results. The expression and correlation between CCN1 and β-catenin in ESCC tissue were examined through
immunohistochemistry and further analyzed in both normal esophageal epithelial cells and ESCC cells through microarray,
functional blocking and in situ protein ligation. We found that nuclear translocation of β-catenin in ESCC cells required high
level of CCN1 as knockdown of CCN1 in ESCC cells reduced β-catenin expression and translocation. Furthermore, we found that
integrin α11 was highly expressed in ESCC tumor tissue and functional blocking integrin α11 diminished CCN1-induced β-catenin
elevation and translocation. Conclusions. Integrin α11 mediated the eﬀect of CCN1 on β-catenin in esophageal epithelial cells.
1.Introduction
While the incidence of most cancers is declining, esophageal
cancer has been continuing its march as the fastest growing
malignancy in the Western world [1]. Nearly 95% of eso-
phageal cancer is esophageal squamous cell carcinoma
(ESCC), whose ﬁve-year survival rate is approximately 15%,
with most patients dying within the ﬁrst year of diagnosis.
Normal esophagus is covered on the lumen side by
stratiﬁed squamous epithelium in which cells are connected
to each other through multiple intercellular locks, such as
tight junctions, adherens junctions and desmosomes. one
of the components of adherens junctions is β-catenin. In
normal epithelium, β-catenin is phosphorylated by glycogen
synthase-3β and casein kinase I to keep its level low, and
any loose β-catenin is degraded and recycled through ubiq-
uitination. However, if for any reason β-catenin is unphos-
phorylated, it can accumulate in the cytoplasm or move into
the nucleus where it becomes a mediator of Wnt signaling
pathway, which could lead to transcriptional activation of
severaloncogenes andpromotecancer[2,3].Forthis reason,
β-catenin translocation has been found in many types of
cancers including ESCC.
CCN1 (formerly known as Cyr61 or IGFBP10) is the ﬁrst
member of the CCN family [4] ,ag r o u po fm a t r i c e l l u l a r
proteins that share a multimodular domain structure and
have been recognized by more and more people as major
players in global control over cellular activities in tissues and
organs[5,6].Assecretedmolecules,CCNproteinsbridgethe
functional and physiological gap between structural macro-
molecules in the extracellular matrix and soluble molecules
such as growth factors and cytokines. They signal through
diﬀerentintegrinreceptorsinacell-andfunction-dependent
manner. Each combination of α and β integrin heterodimer
has its own binding speciﬁcity and signaling properties,
which are further diversiﬁed through alternative splicing2 ISRN Gastroenterology
and/or posttranslational modiﬁcations [7]. To date, almost
all of the known activities of CCN1 are mediated through a
pool of integrin receptors including α6β1, α2β1, αDβ2, αMβ2,
αvβ3, αvβ5,a n dαIIbβ3 [8–14]. For instance, CCN1 promotes
cell adhesion through αVβ3 in endothelial cells [12], through
αIIbβ3 in platelets [14], through α6β1 in ﬁbroblasts [13], and
through αMβ2 in monocytes [11]. On the other hand, while
CCN1 is known to adopt diﬀerent receptors to diversify its
signalinginthesametissue,asbestexempliﬁedinﬁbroblasts,
where it induces cell adhesion through α6β1 and heparan
sulfate proteoglycans, cell migration through αvβ5,a n dc e l l
proliferation through αvβ3 [15], it was also shown to activate
both NF-κB[ 16] and MAPK signaling [17] in breast cancer
cells through the same receptor, namely αvβ3.
Overexpression of CCN1 has been found to activate
β-catenin translocation in several cell systems including
glioma[18],non-small-celllungcancercells[19],andgastric
epithelial cells [20], whereas β-catenin translocation can in
turn promote CCN1 expression through Wnt signaling [21].
Over the last few years, a growing amount of data have
been generated about CCN1 signaling in mesenchymal cells
[8, 13, 15, 22, 23], while its activities in epithelial cells remain
largely unknown. In particular, CCN1 is one of the most
highly expressed proteins in the esophageal epithelium and
has been associated with various pathological conditions,
including ESCC [24], Barrett’s esophagus, and esophageal
adenocarcinoma [25]. Moreover, we recently showed that
CCN1, which is upregulated under acidic conditions [26],
mediates acid-induced esophageal epithelial-mesenchymal
cellular transformation [27], suggesting a critical role in
esophageal malignancy.
2.MaterialsandMethods
2.1. Cell Culture, Transfection, and Treatment. Human eso-
phageal squamous epithelial Het-1A cells (American Type
CultureCollection,Manassas,VA)andesophagealsquamous
carcinoma OE21 cells (Sigma-Aldrich, St. Louis, MO) were
maintained in BEGM plus supplements and RPMI plus
10% serum (Lonza, Walkersville, MD), respectively. To
knock down CCN1, cells were transfected with shRNA
against CCN1 in pRFP-C-RS vector (Origene, Rockville,
MD), which constitutively expresses red ﬂuorescent protein
(RFP) in the transfected cells. Prior to each experiment, cells
were serum-starved overnight and then treated with either
vehicle (control) or recombinant human CCN1 protein
(PeproTech, Rocky Hill, NJ) at 100ng/mL for an indicated
period of time.
2.2. Gene Expression Analysis. Total RNA was extracted from
Het-1A cells using Trizol reagent (Invitrogen, Carlsbad, CA)
and further puriﬁed using RNeasy kit (QIAGEN, Valencia,
CA). Probe was synthesized through reverse transcription
using a GEArray kit (SABiosciences, Frederick, MD) and
labeledwithBiotin-16-dUTP (Roche,Mannheim, Germany)
following the manufacturer protocol. We used GEArray Q
series microarray membranes (SABiosciences) that contain
96 cDNA sequences for extracellular matrix and adhesion
molecules to screen integrins. Brieﬂy, the microarray mem-
brane was prehybridized with the denatured salmon sperm
DNA solution (Sigma-Aldrich) in a hybridization oven
(Fisher Scientiﬁc, Pittsburgh, PA) at 60◦C for one hour and
then hybridized with the labeled probe at the same temper-
ature overnight. The membrane was washed in 2X SSC plus
1% SDS for 2 × 15min at 60◦C and then in 0.1X SSC plus
0.5%SDSforadditional2×15min.Thesignalwasdeveloped
using a chemiluminescent kit (SABiosciences), captured on
X-ray ﬁlm, and quantiﬁed using ImageQuant 3.3 software
(GE Life Sciences, Piscataway, NJ).
Expression of selected genes was also conﬁrmed by real-
time PCR analysis. Brieﬂy, 0.8μgR N Aw a su s e da st e m p l a t e s
to generate cDNA through reverse transcription reaction in
MyCycler(Bio-Rad,Hercules,CA)followingstandardproto-
col (25◦C/10min-55◦C/30min-85◦C/5min-4◦C/5min). β-
actin was included as internal control. Real-time PCR was
performediniCylcer(Bio-Rad)followingtwo-stepmanufac-
turer protocol. Data were analyzed using the ΔΔCt method
basedonatleast3independentexperiments.Brieﬂy,ΔCt was
calculated by subtracting the Ct value of β-actin from the
Ct value for each gene of interest; then ΔΔCt was calculated
by subtracting the ΔCt of the control from the ΔCt of the
treatment for each gene of interest; ﬁnally the fold change
was calculated using the formula: Fold Change = 2(−ΔΔCt).
2.3. Protein Expression Analysis. Protein isolation and West-
ern blotting were done as described in our previous studies
[20, 28]. Brieﬂy, equal amounts of protein were separated
by SDS-PAGE and transferred to nitrocellulose membrane.
Membranes were blocked in 5% milk in phosphate-buﬀered
saline with 1% Tween-20 and incubated in primary antibody
for 2hrs and in HRP-conjugated secondary antibody for
45 minutes. The signal was developed using a chemilumi-
nescent kit, captured on X-ray ﬁlm, and quantiﬁed using
ImageQuant 3.3 software. The following primary antibod-
ies were used: rabbit anti-CCN1 and goat anti-integrin
α11 (Santa Cruz Biotech, Santa Cruz, CA); mouse anti-
phosphoserine/threonine (BD Biosciences, San Diego, CA);
mouse anti-active-β-catenin (Millipore, Billerica, MA); rab-
bit anti-β-catenin (Abcam); mouse anti-β-actin (Sigma-
Aldrich).
For immunoprecipitation, as described in our previous
studies [20, 28], 100μg total protein was incubated with 1μg
rabbit anti-β-catenin antibody for 2 hours at 4◦Co nr o c k e r
prior to addition of agarose A beads (Millipore), and then
the total mixture was incubated again overnight on rocker
at 4◦C. Beads were precipitated and washed three times with
lysis buﬀer prior to ﬁnal resuspension in 2X sample buﬀer.
Samples were boiled for 5 minutes and then separated on 7%
SDS-PAGE gels, transferred to nitrocellulose membrane, and
analyzed by Western blotting as described.
2.4. Immunoﬂuorescence Microscopic Analysis. Cells were
grown in Lab-Tek chamber slides (Nalge, Naperville, IL).
After an appropriate treatment as indicated, cells were
ﬁxed for 10min in cold acetone and incubated in serum-
free Protein Block (Dako, Carpentaria, CA) for 30min toISRN Gastroenterology 3
eliminate possible nonspeciﬁc antibody binding. Then, some
slides were probed with mouse anti-β-catenin antibody
(1:500; Abcam) for 2 hours to detect β-catenin expression
and localization, and control slides were incubated with a
preimmune serum to monitor the speciﬁcity of the antibody.
FITC-conjugated secondary antibody (1:1000; Abcam) was
used to detect the signal.
2.5. Immunohistochemistry. Human esophageal tissue slides
(Capital Biosciences, Rockville, MD) were deparaﬃnized in
Histoclear solution (National Diagnostics, Atlanta, GA) and
rehydrated in a series of ethanol. Antigens were retrieved
by repeatedly microwave boiling in 0.01M sodium citrate
buﬀer(pH6.0).EndogenousperoxidasewasblockedinDako
reagent for 10 minutes. Slides were then incubated with the
following primary antibodies at 4◦C overnight: rabbit anti-
CCN1(1:200),rabbitanti-β-catenin(1:500),andgoatanti-
integrin α11 (1:50). The LSAB+kit (Dako) was used to de-
velop a signal.
2.6. Detection of Protein-Protein Interactions by Proximity
Ligation. Protein-protein interactions were analyzed in situ
using the duolink PLA-probe detection system (Olink Bio-
science/Axxora LLC, San Diego, CA). Brieﬂy, cells were
cultured on cover slips, ﬁxed in cold acetone, blocked and
incubated in a primary antibody as described above for cell
staining, followed by 2-hour incubation in rabbit and goat
PLA PLUS and PLA MINUS probes, 15-minute hybridiza-
tion, 15-minute ligation, 90-minute ampliﬁcation, and 60-
minute detection according to the manufacturer protocol.
Goat anti-integrin α11 was coupled with rabbit anti-CCN1.
To maximize signal strength, samples were incubated in pri-
mary antibody overnight (4◦C) and PLA probes were used at
a 1/2.5 dilution. All steps after primary antibody incubation
were carried out at 37◦C. Nuclei were counterstained with
Hoechst 33342 (blue). This system uses special secondary
antibodies containing a short DNA strand (PLA probes),
which can hybridize and form a circularized oligo that
can be ampliﬁed and detected as a discrete ﬂuorescent dot
(individual interaction between two molecules) when two
opposite probes come in close proximity (less than 40nm)
[29].
2.7. Integrin Functional Blockage. Cells were serum starved
overnight in basal medium. Where indicated, cells were then
preincubated with either diluted preimmune serum (con-
trol) or the antibody against the extracellular domain of in-
tegrin α11 at 50μg/mL in fresh basal medium for 3 hours.
Recombinant CCN1 protein (100ng/mL) was then added
to the medium, and cells were incubated again overnight.
Nontreated cells and CCN1-treated cells cultured in the
absence of antibody pretreatment were included as negative
and positive control respectively. The eﬀect of integrin
blockage on CCN1 signaling was assessed by β-catenin
nuclear translocation through immunoﬂuorescence micro-
scopic analysis as well as by β-catenin activation through
immunoprecipitation and Western blot analysis as described
above.
2.8. Statistical Analysis. All experiments were performed at
least in triplicates. All numerical data were analyzed by
single-classiﬁcation one-way ANOVA, and P<0.05 was con-
sidered signiﬁcant.
3. Results
3.1. Knockdown of CCN1 in ESCC Curtails β-Catenin Expres-
sion and Translocation. Comparing to normal esophageal
mucosa in which β-catenin was neatly localized to the
cell membrane (Figures 1(a) and 1(g)), β-catenin in ESCC
was not only elevated but also mostly dissociated from
the membrane and accumulated in the cytoplasm, and
some even appeared in the nucleus (Figures 1(b), 1(c) and
1(i)). CCN1, correspondingly, was heavily elevated in ESCC
(Figures 1(e) and 1(f)), compared to normal esophageal
mucosa in which CCN1 was mainly conﬁned to the basal
cells and gradually faded away towards the mucosal surface
(Figure 1(d)),indicatinganinvolvementincellproliferation.
After an incubation with recombinant human CCN1 protein
at 100ng/mL for 6 hours, normal esophageal Het-1A cells
displayed a heavy accumulation of β-catenin in both the
cytoplasm and the nucleus (Figure 1(h)), similar to what was
observed in ESCC tumor tissue, whereas in ESCC OE21 cells
inwhichβ-cateninwasoriginallyexpressedinthecytoplasm,
adding exogenous CCN1 made it more concentrated in the
nuclear areas (Figure 1(j)).
To know whether β-catenin elevation and transloca-
tion in ESCC are associated with CCN1 upregulation, we
transfected OE21 cells with RFP-conjugated shRNA against
CCN1, and then we stained the cells for β-catenin and
detected it with a FITC-conjugated secondary antibody. In
those transfected cells (easily identiﬁed by the bright red ﬂu-
orescence), β-catenin level was decreased and its distribution
was more conﬁned to the cell membrane (Figures 2(a) and
2(b)), indicating that CCN1 is responsible (at least partially
if not all) for β-catenin elevation and translocation in ESCC.
Western blot analysis also conﬁrmed the downregulation of
β-catenin in OE21 cells by CCN1 knockdown (Figure 2(c)).
3.2. CCN1 Upregulates Expression of ITGA11 in Esophageal
Epithelial Cells. Based on what we discussed previously, that
is, CCN1 signals through diﬀerent integrin receptors in a
cell-dependent manner, we were interested to know what
integrin(s) mediates CCN1-activated β-catenin transloca-
tion in esophageal epithelial cells. Since CCN1 signaling in
esophagealepithelialcellshasneverbeenstudied,wedecided
to screen the integrin library to look for candidate(s). Out
of 16 α-a n d8β-integrins examined (Figure 3(a)), only two
responded to CCN1 treatment signiﬁcantly: ITGA11 was
increased by 143.98-fold and 61.78-fold at 2 and 12 hours
respectively, and ITGB5 was increased by 5.68-fold and 4.71-
fold correspondingly (all P<0.01). Since integrin β5 is a
known receptor of CCN1 [13, 15], integrin α11 was chosen
f o rf u r t h e ri n v e s t i g a t i o n .
To determine whether there is a direct interaction
between CCN1 and integrin α11, we used a novel protein-
protein interaction technique (DUOLINK system). Nowa-
days, more and more studies use this technology to visualize4 ISRN Gastroenterology
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Figure 1: CCN1 induces β-catenin translocation in esophageal epithelial cells. (a) In normal esophageal mucosa, β-catenin is localized
to the cell membrane (250x). (b) In ESCC tumor tissue, β-catenin expression is highly elevated (250x). (c) β-catenin in ESCC tissue is
mainly localized in the cytoplasm and some appears in the nucleus as well (600x). (d) In normal esophageal mucosa, CCN1 is primarily
expressed in the basal cells (250x). (e) CCN1 expression is elevated in ESCC tumor tissue (250x). (f) CCN1 is localized to both cellular and
extracellular matrix in ESCC tumor tissue (600x). (g) In Het-1A cells, β-catenin is neatly conﬁned to intercellular connections. (h) Under
CCN1 treatment, β-catenin in Het-1A cells accumulates in the cytoplasm and the nucleus. (i) In OE21 cells, β-catenin appears in both the
cytoplasm and the cell membrane. (j) Under CCN1 treatment, β-catenin in OE21 cells becomes more concentrated in the nuclear area.
in situ ligand-receptor binding [30, 31]. In the CCN1-
treatedHet-1Acells,massivesignals(reddots)weredetected,
reﬂecting active interactions between these two molecules
(Figure 4(b)). However, some signals were also detected in
the nontreated cells (Figure 4(a)), indicating the existence of
naturalinteractionsbetweenendogenousCCN1andintegrin
α11. On the other hand, blocking CCN1 with excessive
antibody diminished the signal, conﬁrming the speciﬁcity of
the interaction (Figure 4(c)).
3.3. Integrin α11 Is Overexpressed in ESCC. Based on our
results shown above, that is, CCN1 is elevated in ESCC
and it can increase integrin α11 expression, we predicted
that integrin α11 expression would likely be elevated in
ESCC. To test our hypothesis, we compared integrin α11
expression in ESCC tumor tissue with normal esophageal
mucosa (Figure 4(d)) by immunohistochemistry. Integrin
α11 was found highly elevated in ESCC (Figure 4(e)), and
somewasneatlylocalizedtothecellmembrane(Figure 4(f)).
3.4. Integrin α11 Mediates CCN1-Induced β-Catenin Translo-
cation. Naturally, next we wanted to know whether integrin
α11 was involved in CCN1-induced β-catenin translocation
in esophageal cells. We treated Het-1A cells with recombi-
nant CCN1 for 12 hours, the level of the active form of
β-catenin (dephosphorylated on serine-37 or threonine-41)
was increased by 109.1% (P<0.01), which was conﬁrmed
by reprobing the blots for phosphorylated serine/threonine
(Figure 5(a)). However, when excessive anti-integrin α11
antibodywasaddedtothecellculture,CCN1failedtoinduce
activation of β-catenin (Figure 5(a)). These results were also
conﬁrmed by immunoﬂuorescence microscopic analysis,
where CCN1 failed to induce β-catenin translocation in the
presence of integrin α11 antibody and β-catenin remained
predominantlyin the membrane instead (Figure 5(b)), sug-
gesting that integrin α11 is required to transduce CCN1-
mediated β-catenin translocation in esophageal epithelial
cells.
4. Discussion
While CCN1 is best known for its angiogenic activity [32,
33], its role in epithelial cells is largely unknown. Our recent
study demonstrates that CCN1 can induce a transient
epithelial-mesenchymal transition during gastric ulcer heal-
ing to facilitate the process of re-epithelialization [20]. A
similar eﬀect was also noted in esophageal epithelial cellsISRN Gastroenterology 5
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Figure 2:KnockdownofCCN1inOE21ESCCcells(OE2CCN1−)reducesthelevelofβ-catenin.(a)Underadual ﬁlter,theshRNAtransfected
cells display bright red ﬂuorescence due to expression of RFP, while β-catenin is identiﬁe in green by FITC-conjugated antibody. (b) In the
same view under FITC ﬁlter, the shRNA transfected cells display low level of β-catenin compared to nontransfected cells. (c) Western blot
analysis shows reduced expression of β-catenin in OE21CCN1− cells.
[26], suggesting a protective part for CCN1 in normal
epithelial cells. In cancers, on the other hand, CCN1 is
like a double-edged sword: in gastric cancer it was found
to enhance tumorigenicity [34], while in squamous lung
carcinoma it served the opposite role [35]. Furthermore,
the expression level of CCN1 is highly dependent on the
type and the stage of the cancer. Elevation of CCN1 has
b e e nf o u n di nb r e a s tc a n c e r[ 16], pancreatic cancer [36],
and gliomas [18], while in endometrial cancer [37] and lung
carcinoma [35], CCN1 level is decreased. More complex
or even conﬂicting results have been reported in some
other cancers. For instance, in 1998, CCN1 downregulation
was reported in prostate cancer [38] ,w h i l em o r er e c e n t
studies showed the opposite results [36, 37]. In colorectal
cancer, CCN1 mRNA was elevated compared with normal
colon, but it was reduced in more advanced stages [38]. A
similar trend was also noted in our study on esophageal
adenocarcinoma development from gastroesophageal reﬂux
disease, in which CCN1 was highly elevated in acid reﬂux
condition and continued its overexpression at the lower
level during metaplastic transformation, but it dropped
in the advanced adenocarcinoma [39]. Recently, CCN1
upregulation has been reported in ESCC [24, 40, 41], in
which high expression of CCN1 was noted in association
with poor survival of ESCC patients [24].
In our previous study, we found that CCN1 can induce a
transient β-catenin translocation in normal gastric epithelial
cells [20] and thereby promotes ulcer healing process by
accelerating epithelialization. Once the wound is healed,
β-catenin can return to its usual level and function. In
this current study, we showed that β-catenin elevation
and translocation in ESCC tumor cells are dependent on
high level of CCN1. Knockdown of CCN1 can reduce β-
catenin. β-catenin is a key player in Wnt signaling, and
its activation/translocation can lead to expression of a
number of growth-related genes. Some of these genes are
oncogenic (e.g., c-myc, c-jun), which can contribute to
cancerdevelopment.Inaddition,β-catenintranslocationcan6 ISRN Gastroenterology
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Figure 3:CCN1upregulatesgeneexpressionofITGA11andITGB5inesophagealepithelialcells.Cellswereculturedintheabsence(control)
orpresenceofCCN1forthetimesindicated.TotalRNAwasisolatedandreverse-transcribedwithBiotin-16-dUTPtogeneratecDNAprobes,
which were then hybridized to the cDNA microarrays. (a) Array layout with integrins is marked in bold. Integrins further analyzed in the
study are in red. (b) Gene expression proﬁle with marked (circled) integrins of interest. ITGA11 and ITGB5 are upregulated by CCN1.
also destabilize intercellular connection, facilitating cancer
metastasis. CCN1 just happens to be one of Wnt signaling
targets. Therefore, these two molecules can form a CCN1-β-
catenin-CCN1 loop to amplify the signal, thereby to acceler-
ate wound healing or to promote oncogenesis, depending on
the context. Further studies on the relationship of these two
proteins would be very rewarding.
CCN1 functions through diﬀerent integrin receptors in a
tissue-dependentmanner.Outof26knownintegrins,atleast
8 have been found to mediate CCN1 actions in various cells.ISRN Gastroenterology 7
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Figure 4: Integrin α11 is elevated in ESCC tumor tissue, and CCN1 has direct interaction with integrin α11 esophageal epithelial cells. (a)
Endogenous CCN1 interacts with integrin α11 in Het-1A cells although signals are weak (control). (b) After Het-1A cells were treated with
CCN1 for 6 hours, the signals reﬂecting CCN1 and integrin α11 interaction were greatly increased. (c) Adding CCN1 antibody to the cell
culture eliminated the signal of CCN1-integrin α11 interaction. (d) Integrin α11 expression in normal esophageal mucosa (250x). (e) Integrin
α11 is elevated in ESCC tumor tissue (250x). (f) Integrin α11 is mainly localized to the cell membrane in ESCC tumor (600x).
−
−− Anti-integrin α11
CCN1
Active-β-catenin
Phos-β-catenin
Total-β-catenin
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Figure 5: Integrin α11 mediates CCN1-induced β-catenin activation and translocation. (a) Het-1A cells were pretreated with either
preimmune serum (control) or anti-integrin α11 antibody cultured in the absence (−) or presence (+) of CCN1 overnight. β-catenin was
pulled down from the cells lysates through immunoprecipitation, subsequently analyzed by Western blot for expression of total β-catenin,
active β-catenin (dephosphorylated at Ser37 or Thr41), and Ser/Thr-phosphorylated β-catenin. (b) Immunoﬂuorescence microscopic
analysis shows that blocking integrin α11 with a speciﬁc antibody prevents CCN1 to induce β-catenin translocation.
The context dependency of CCN1 is reﬂected in its receptor
selection. Here we showed that integrin α11 is epithelial cells.
ITGA11, the gene encoding integrin α11 protein, was cloned
and sequenced a decade ago by two independent groups [42,
43].Bothgroupsexaminedtheexpressionpatternofintegrin
α11 in adult tissue and found that it was mainly expressed
in muscular-rich organs such as uterus, heart, and skeletal
muscle.Theyalsoidentiﬁedmoderateexpressionsofintegrin
α11 in the gastrointestinal tract, including the stomach, the
intestine, and the colon, although the esophagus was not ex-8 ISRN Gastroenterology
amined. Up to date, there are less than 20 studies on ITGA11
published, most of which focus on mesenchymal tissues,
where integrin α11 mediates such processes as migration of
embryonic ﬁbroblasts [44], tooth eruption [45], and cor-
neal development and disease [46]. On the other hand, the
expressionandfunctionofintegrinα11 inepithelialcellshave
never been fully investigated. In this study, we showed
that ITGA11 is normally expressed at minimal levels in
esophageal epithelial cells, but it can be dramatically upregu-
lated by CCN1, a feedback mechanism that CCN1 is known
to employ for some of its receptors in other tissues. Con-
sistent with the possible role of integrin α11 as a CCN1 re-
ceptor, a direct interaction between these two proteins was
demonstrated, and blocking integrin α11 function prevented
CCN1 from eliciting its downstream signals in these cells.
In conclusion, our study has demonstrated that the ele-
vation and translocation of β-catenin in ESCC require high
levelofCCN1,andintegrinα11,whichhassofarbeenstudied
mostly in mesenchymal tissues, mediates this process. Given
the importance of nuclear β-catenin in cancer progression
[47, 48], particularly in ESCC [49, 50] and esophageal ade-
nocarcinoma [51, 52], our ﬁndings could be one step closer
to better understanding of the molecular progression of
esophageal malignancy.
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